Current concepts in premature ovarian insufficiency

Women's Health

Volumn 11, Issue 2, 2015, Pages 169-182

  Maclaran, Kate ^a   Panay, Nick ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN CHARLOTTE S AND CHELSEA HOSPITAL   (United Kingdom)

Author keywords

hormone therapy; ovarian reserve; premature menopause; premature ovarian failure; premature ovarian insufficiency; primary ovarian insufficiency; sex steroid deficiency

Indexed keywords

CAFFEINE; CALCIUM; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; FOLLITROPIN; GABAPENTIN; GROWTH DIFFERENTIATION FACTOR 9; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; NORADRENALIN UPTAKE INHIBITOR; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; PROLACTIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE; TESTOSTERONE; VITAMIN D; ANDROGEN;

AGE; ALCOHOL WITHDRAWAL; ANDROGEN THERAPY; ATAXIA TELANGECTASIA; ATM GENE; AUTOIMMUNE DISEASE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; AUTOSOMAL DISORDER; BLEPHAROPHIMOSIS; BONE DENSITY; CANCER THERAPY; CHICKENPOX; CONTRACEPTION; CRYOPRESERVATION; CYP17A1 GENE; CYP19 GENE; CYTOMEGALOVIRUS INFECTION; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG MEGADOSE; EIF2B GENE; ENVIRONMENTAL FACTOR; EPICANTHUS INVERSUS SYNDROME TYPE 1; ETHNIC DIFFERENCE; FAMILY COUNSELING; FEMALE; FERTILITY; FERTILITY PRESERVATION; FERTILIZATION IN VITRO; FIGLA GENE; FMRI GENE; FOXL2 GENE; FRAGILE X SYNDROME; GALACTOSEMIA; GALT GENE; GDF9 GENE; GENETIC ASSOCIATION; GENETICS; GNAS1 GENE; GYNECOLOGIC CANCER; HERITABILITY; HERPES SIMPLEX; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IATROGENIC DISEASE; INCIDENCE; INFECTION; KARYOTYPE; LH GENE; LIFE EXPECTANCY; LIFE SATISFACTION; LIFESTYLE MODIFICATION; LONG TERM CARE; MALARIA; MENOPAUSE; MENTAL HEALTH; MUMPS; NOBOX GENE; NR5A1 GENE; OVARIAN LEUKODYSTROPHY; OVARIAN RESERVE; OVARY FUNCTION; OVARY INSUFFICIENCY; OVULATION; PATHOPHYSIOLOGY; PATIENT COUNSELING; PHYSIOTHERAPY; POLG GENE; POPULATION RESEARCH; PRACTICE GUIDELINE; PREMATURE OVARIAN FAILURE; PROGRESSIVE EXTERNAL OPTHALMOPLEGIA; PSEUDOHYPOPARATHYROIDSIM TYPE 1A; PTOSIS; QUALITY OF LIFE; RESISTANCE TRAINING; REVIEW; RISK FACTOR; SALPINGOOOPHORECTOMY; SELF ESTEEM; SEX CHROMOSOME ABERRATION; SEXUAL FUNCTION; SMOKING; SMOKING CESSATION; THYROID FUNCTION; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TUBERCULOSIS; TURNER SYNDROME; VITAMIN SUPPLEMENTATION; WOMEN'S HEALTH; X CHROMOSOME; BODY IMAGE; COMPLICATION; HORMONE SUBSTITUTION; INFERTILITY, FEMALE; PHYSIOLOGY; PRIMARY OVARIAN INSUFFICIENCY; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

AGE FACTORS; ANDROGENS; BODY IMAGE; CHROMOSOMES, HUMAN, X; DIAGNOSIS, DIFFERENTIAL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INFECTION; INFERTILITY, FEMALE; MENTAL HEALTH; OVARIAN RESERVE; PRIMARY OVARIAN INSUFFICIENCY; QUALITY OF LIFE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; WOMEN'S HEALTH;

EID: 84925218054     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.14.82     Document Type: Review

References (122)

1. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet. Gynecol. 67, 604-606 (1986).
2. Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin. Endocrinol. (Oxf.) 68, 499-509 (2008).
3. Kalu E, Panay N. Spontaneous premature ovarian failure: management challenges. Gynecol. Endocrinol. 24, 273-279 (2008).
4. Alzubaidi NH, Chapin HL, Vanderhoof VH et al. Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure. Obstet. Gynecol. 99, 720-725 (2002).
5. Chemaitilly W, Mertens AC, Mitby P et al. Acute ovarian failure in the childhood cancer survivor study. J. Clin. Endocrinol. Metab. 91, 1723-1728 (2006).
6. Sklar CA, Mertens AC, Mitby P et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J. Natl Cancer Inst. 98, 890-896 (2006).
7. Islam R, Cartwright R. The impact of premature ovarian failure on quality of life: results from the UK 1958 Birth Cohort. Presented at: 27th Annual Meeting of ESHRE. Stockholm, Sweden, 3-6 July 2011.
8. Luborsky JL, Meyer P, Sowers MF et al. Premature menopause in a multi-ethnic population study of the menopause transition. Hum. Reprod. 18, 199-206 (2003).
9. Cramer DW, Xu H, Harlow BL. Family history as a predictor of early menopause. Fertil. Steril. 64, 740-745 (1995).
10. van Kasteren YM, Hundscheid RD, Smits AP, Cremers FP, van Zonneveld P, Braat DD. Familial idiopathic premature ovarian failure: an overrated and underestimated genetic disease? Hum. Reprod. 14, 2455-2459 (1999).
11. Morris DH, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Familial concordance for age at natural menopause: results from the Breakthrough Generations Study. Menopause 18, 956-961 (2011).
12. Bentzen JG, Forman JL, Larsen EC et al. Maternal menopause as a predictor of anti-Mullerian hormone level and antral follicle count in daughters during reproductive age. Hum. Reprod. 28, 247-255 (2013).
13. Chang SH, Kim CS, Lee KS et al. Premenopausal factors influencing premature ovarian failure and early menopause. Maturitas 58, 19-30 (2007).
14. Nelson LM. Clinical practice. Primary ovarian insufficiency. N. Engl. J. Med. 360, 606-614 (2009).
15. Janse F, Knauff EA, Niermeijer MF et al. Dutch Premature Ovarian Failure Consortium. Similar phenotype characteristics comparing familial and sporadic premature ovarian failure. Menopause 17, 758-765 (2010).
16. Jiao X, Qin C, Li J et al. Cytogenetic analysis of 531 Chinese women with premature ovarian failure. Hum. Reprod. 27, 2201-2207 (2012).
17. Rebar RW, Erickson GF, Yen SS. Idiopathic premature ovarian failure: clinical and endocrine characteristics. Fertil. Steril. 37, 35-41 (1982).
18. Sybert VP, McCauley E. Turner's syndrome. N. Engl. J. Med. 351, 1227-1238 (2004).
19. Zhao H, Chen ZJ. Genetic association studies in female reproduction: from candidate-gene approaches to genomewide mapping. Mol. Hum. Reprod. 19, 644-654 (2013).
20. Cox L, Liu JH. Primary ovarian insufficiency: an update. Int. J. Womens. Health 6, 235-243 (2014).
21. Persani L, Rossetti R, Di Pasquale E, Cacciatore C, Fabre S. The fundamental role of bone morphogenetic protein 15 in ovarian function and its involvement in female fertility disorders. Hum. Reprod. Update 20, 869-883 (2014).
22. Laissue P, Christin-Maitre S, Touraine P et al. Mutations and sequence variants in GDF9 and BMP15 in patients with premature ovarian failure. Eur. J. Endocrinol. 154, 739-744 (2006).
23. Di Pasquale E, Rossetti R, Marozzi A et al. Identification of new variants of human BMP15 gene in a large cohort of women with premature ovarian failure. J. Clin. Endocrinol. Metab. 91, 1976-1979 (2006).
24. Rossetti R, Di Pasquale E, Marozzi A et al. BMP15 mutations associated with primary ovarian insufficiency cause a defective production of bioactive protein. Hum. Mutat. 30, 804-810 (2009).
25. Tiotiu D, Alvaro Mercadal B, Imbert R et al. Variants of the BMP15 gene in a cohort of patients with premature ovarian failure. Hum. Reprod. 25, 1581-1587 (2010).
26. Willemsen R, Levenga J, Oostra BA. CGG repeat in the FMR1 gene: size matters. Clin. Genet. 80, 214-225 (2011).
27. Murray A, Schoemaker MJ, Bennett CE et al. Population-based estimates of the prevalence of FMR1 expansion mutations in women with early menopause and primary ovarian insufficiency. Genet. Med. 16, 19-24 (2014).
28. Marozzi A, Vegetti W, Manfredini E et al. Association between premature ovarian failure and fragile x premutation. Hum. Reprod. 15, 197-202 (2000).
29. Murray A. Premature ovarian failure and the FMR1 gene. Semin. Reprod. Med. 18, 59-66 (2000).
30. Bussani C, Papi L, Sestini R et al. Premature ovarian failure and fragile X premutation: a study on 45 women. Eur. J. Obstet. Gynecol. Reprod. Biol. 112, 189-191 (2004).
31. Persani L, Rossetti R, Cacciatore C. Genes involved in human premature ovarian failure. J. Mol. Endocrinol. 45, 257-279 (2010).
32. Silva CA, Yamakami LY, Aikawa NE, Araujo DB, Carvalho JF, Bonfa E. Autoimmune primary ovarian insufficiency. Autoimmun. Rev. 13, 427-430 (2014).
33. Bakalov VK, Anasti JN, Calis KA et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46, XX spontaneous premature ovarian failure. Fertil. Steril. 84, 958-965 (2005).
34. Novosad JA, Kalantaridou SN, Tong ZB et al. Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation. BMC Womens Health 3, 2 (2003).
35. Morrison JC, Givens JR, Wiser WL et al. Mumps oophoritis: a cause of premature menopause. Fertil. Steril. 26, 655-659 (1975).
36. Ohl J, Partisani M, Demangeat C, Binder-Foucard F, Nisand I, Lang JM. Alterations of ovarian reserve tests in human immunodeficiency virus (HIV)-infected women. Gynecol. Obstet. Fertil. 38, 313-317 (2010).
37. De Pommerol M, Hessamfar M, Lawson-Ayayi S et al. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA). Int. J. STD AIDS 22, 67-72 (2011).
38. Imai K, Sutton MY, Mdodo R, Del Rio C. HIV and menopause: a systematic review of the effects of HIV infection of age at menopause and the effects if menopause on response to antiretroviral therapy. Obstet. Gynecol. Int. 340309 (2013).
39. Rodriguez-Wallberg KA, Oktay K. Fertility preservation during cancer treatment: clinical guidelines. Cancer Manag. Res. 6, 105-115 (2014).
40. Panay N, Fenton A. Premature ovarian failure: a growing concern. Climacteric 11, 1-3 (2008).
41. th World Congress of Gynecological Endocrinology. Florence, Italy, 7-10 March 2012,
42. Green DM, Sklar CA, Boice JD Jr et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J. Clin. Oncol. 27, 2374-2381 (2009).
43. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet. Gynecol. 113, 957-966 (2009).
44. NICE. Familial breast cancer: summary of updated NICE guidance. BMJ 346, f3829 (2013).
45. Metcalfe KA, Ghadirian P, Rosen B et al. Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Open Med. 2, 92-98 (2007).
46. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int. J. Cancer 122, 2017-2022 (2008).
47. Domchek S, Friebel T, Singer C. Association of riskreducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304, 967-975 (2010).
48. Marchetti C, Iadarola R, Palaia I et al. Hormone therapy in oophorectomized BRCA1/2 mutation carriers. Menopause 21, 763-768 (2014).
49. Finch A, Evans G, Narod SA. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health (Lond. Engl.) 8, 543-555 (2012).
50. Jadoul P, Donnez J. How does bone marrow transplantation affect ovarian function and fertility? Curr. Opin. Obstet. Gynecol. 24, 164-171 (2012).
51. Kaump GR, Spies JB. The impact of uterine artery embolization on ovarian function. J. Vasc. Interv. Radiol. 24, 459-469 (2013).
52. Sahmay S, Usta TA, Erel T, Atakul N, Aydogan B. Elevated LH levels draw a stronger distinction than AMH in premature ovarian insufficiency. Climacteric 17, 197-203 (2014).
53. Tremellen KP, Kolo M, Gilmore A, Lekamge DN. Antimullerian hormone as a marker of ovarian reserve. Aust. N. Z. J. Obstet. Gynecol. 45, 20-24 (2005).
54. Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil. Steril. 99, 963-969 (2013).
55. Dewailly D, Andersen CY, Balen A et al. The physiology and clinical utility of anti-mullerian hormone in women. Hum. Reprod. Update 20, 370-385 (2014).
56. Leader B, Baker VL. Maximising the clinical utility of antimullerian hormone testing in women's health. Curr. Opin. Obstet. Gynecol. 26, 226-236 (2014).
57. Dolleman M, Depmann M, Eijkemans MJ et al. Antimullerian hormone is a more accurate predictor of individual time to menopause than mother's age at menopause. Hum. Reprod. 29, 584-591 (2014).
58. Ramezani Tehrani F, Dolleman M, van Disseldorp J et al. Predicting menopausal age with anti-mullerian hormone: a cross-validation study of two existing models. Climacteric 10, 1-8 (2014).
59. La Marca A, Sighinolfi G, Papaleo E et al. Prediction of age at menopause from assessment of ovarian reserve may be improved by using body mass index and smoking status. PLoS ONE 8, e57005 (2013).
60. Su H, Sammel MD, Homer MV et al. Comparability of antimullerian hormone levels among commercially available immunoassays. Fertil. Steril. 101, 1766-1772 (2014).
61. British Menopause Society (BMS). Premature Menopause. British Menopause Society Council Consensus Statement. (2007). www.thebms.org.uk
62. Mittal M, Savvas M, Narvekar N, Panay N, Hamoda H. A cross-sectional national questionnaire survey assessing the clinical attitudes of members of the British Menopause Society to the management of women with premature ovarian insufficiency. Post Reprod. Health 20, 990-997 (2014)
63. Popat VB, Vanderhoof VH, Calis KA, Troendle JF, Nelson LM. Normalization of serum luteinizing hormone levels in women with 46, XX spontaneous primary ovarian insufficiency. Fertil. Steril. 89, 429-433 (2008).
64. Renoux C, Dell'aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J. Thromb. Haemost. 8, 979-986 (2010).
65. Popat VB, Calis KA, Kalantaridou SN et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J. Clin. Endocrinol. Metab. 99, 3418-3426 (2014).
66. Baker VL. Primary ovarian insufficiency in the adolescent. Curr. Opin. Obstet. Gynecol. 25, 375-381 (2013).
67. Panay N, Hamoda H, Arya R, Savvas M; British Menopause Society and Women's Health Concern. The 2013 British Menopause Society & Women's Health Concern recommendations on hormone replacement therapy. Menopause Int. 19, 59-68 (2013).
68. Mittal M, Savvas M, Arya R et al. A randomised controlled trial comparing the effects of micronized progesterone to medroxyprogesterone acetate on cardiovascular health, lipid metabolism and the coagulation cascade in women with premature ovarian insufficiency: study protocol and review of the literature. Menopause Int. 19, 127-132 (2013).
69. Guttman H, Weiner E, Nikolske, et al. Choosing an oestrogen replacement therapy in young adult women with Turner syndrome. Clin. Endocrinol. 54, 159-164 (2001).
70. Langrish JP, Mills NL, Bath LE et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension 53, 805-811 (2009).
71. Crofton PM, Evans N, Bath LE et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin. Endocrinol. (Oxf.) 73, 707-714 (2010).
72. Cartwright B, Robinson J, Rymer J. Treatment of premature ovarian failure trial: description of an ongoing clinical trial. Menopause Int. 16, 18-22 (2010).
73. Gibson-Helm M, Teede H, Vincent A. Symptoms, health behaviour and understanding of menopause therapy in women with premature menopause. Climacteric 17, 1-8 (2014).
74. van der Stege JG, Groen H, van Zadelhoff SJ et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 15, 23-31 (2008).
75. De Almeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian failure. Menopause 18, 262-266 (2011).
76. Graziottin A, Basson R. Sexual dysfunction in women with premature menopause. Menopause 11, 766-777 (2004).
77. Janse F, Tanahatoe SJ, Eijkemans MJ, Fauser BC. Testosterone concentrations, using different assays, in different types of ovarian insufficiency: a systematic review and meta-analysis. Hum. Reprod. Update 18, 405-419 (2012).
78. Guerrieri GM, Martinez PE, Klug SP et al. Effects of physiological testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency. Menopause 21, 952-961 (2014).
79. Schmidt PJ, Cardoso GM, Ross JL et al. Shyness, social anxiety, and impaired self-esteem in Turner syndrome and premature ovarian failure. JAMA 295, 1374-1376 (2006).
80. Liao KL, Wood N, Conway GS. Premature menopause and psychological well-being. J. Psychosom. Obstet. Gynaecol. 21, 167-174 (2000).
81. Singer D, Mann E, Hunter MS, Pitkin J, Panay N. The silent grief: psychosocial aspects of premature ovarian failure. Climacteric 14, 428-437 (2011).
82. The Daisy Network Premature Menopause Support Group. www.daisynetwork.org
83. Ossewaarde ME, Bots ML, Verbeek AL et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 16, 556-562 (2005).
84. van Der Voort DJ, van Der Weijer PH, Barentsen R. Early menopause: increased fracture risk at older age. Osteoporos. Int. 14, 525-530 (2003).
85. van der Klift M, de Laet CE, McCloskey EV et al. Risk factors for incident vertebral fractures in men and women: the Rotterdam Study. J. Bone Miner. Res. 19, 1172-1180 (2004).
86. Jacobsen BK, Knutsen SF, Fraser GE. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J. Clin. Epidemiol. 52, 303-307 (1999).
87. Kalantaridou SN, Naka KK, Papanikolaou E et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J. Clin. Endocrinol. Metab. 89, 3907-3913 (2004).
88. Knauff EA, Westerveld HE, Goverde AJ et al. Lipid profile of women with premature ovarian failure. Menopause 15, 919-923 (2008).
89. Corrigan EC, Nelson LM, Bakalov VK et al. Effects of ovarian failure and X-chromosome deletion on body composition and insulin sensitivity in young women. Menopause 13, 911-916 (2006).
90. Eshtiaghi R, Esteghamati A, Nakhjavani M. Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas 65, 262-266 (2010).
91. Rocca WA, Grossardt BR, Miller VM, Shuster LT, Brown RD Jr. Premature menopause or early menopause and risk of ischaemic stroke. Menopause 19, 272-277 (2012).
92. Jacoby VL, Grady D, Wactawski-Wende J et al. Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Arch. Intern. Med. 171, 760-768 (2011).
93. Rocca WA, Bower JH, Maraganore DM et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 70, 200-209 (2009).
94. Soni M, Hogervorst E. Premature ovarian insufficiency and neurological function. Minerva Endocrinol. 39, 189-199 (2014).
95. Ryan J, Scali J, Carrière I et al. Impact of a premature menopause on cognitive function in later life. BJOG doi: 10.1111/1471-0528.12828 (2014) (Epub ahead of print).
96. Nelson LM, Covington SN, Rebar RW. An update: spontaneous premature ovarian failure is not an early menopause. Fertil. Steril. 83, 1327-1332 (2005).
97. Laml T, Huber JC, Albrecht AE, Sintenis WA, Hartmann BW. Unexpected pregnancy during hormone-replacement therapy in a woman with elevated follicle-stimulating hormone levels and amenorrhoea. Gynecol. Endocrinol. 13, 89-92 (1999).
98. Dragojevi-Diki S, Raki S, Nikoli B, Popovac S. Hormone replacement therapy and successful pregnancy in a patient with premature ovarian failure. Gynecol. Endocrinol. 25, 769-772 (2009).
99. Bidet M, Bachelot A, Touraine P. Premature ovarian failure: predictability of intermittent ovarian function and response to ovulation induction agents. Curr. Opin. Obstet. Gynecol. 20, 416-420 (2008).
100. Buckler H, Healy D, Burger H. Does gonadotropin suppression result in follicular development in premature ovarian failure? Gynaecol. Endocrinol. 7, 123-128 (1993).
101. Tartagni M, Cicinelli E, De Pergola G et al. Effects of pretreatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo-controlled trial. Fertil. Steril. 87, 858-861 (2007).
102. Mamas L, Mamas E. Premature ovarian failure and dehydroepiandrosterone. Fertil. Steril. 91, 644-646 (2009).
103. Yeung TW, Li RH, Lee VC, Ho PC, Ng EH. A randomized double-blinded placebo-controlled trial on the effect of dihydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency. J. Clin. Endocrinol. Metab. 98, 380-388 (2013).
104. Ben-Nagi J, Panay N. Premature ovarian insufficiency: how to improve reproductive outcome? Climacteric 17, 342-346 (2012).
105. Loren AW, Mangu PB, Beck LN et al. American Society of Clinical Oncology. Fertility preservation for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 31, 2500-2510 (2013).
106. National Institute for Health Care and Excellence. Fertility: assessment and treatment for people with fertility problems. http://publications.nice.org.uk/fertility-cg156
107. Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F et al. Gonadotrophin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat. Rev. 40, 675-683 (2014).
108. Wong KM, Mastenbroek S, Repping S. Cryopreservation of human embryos and it contribution to in vitro fertilization success rates. Fertil. Steril. 102, 19-26 (2014).
109. Evans J, Hannan NJ, Edgell TA et al. Fresh versus frozen embryo transfer: backing clinical decisions with scientific and clinical evidence. Hum. Reprod. Update 20, 808-821 (2014).
110. Grifo JA, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil. Steril. 93, 391-396 (2010).
111. Practice Committees of American Society for Reproductive Medicine Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil. Steril. 99, 37-43 (2013).
112. Oktay K, Karlikaya G. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N. Engl. J. Med. 342, 1919 (2000).
113. Donnez J, Silber S, Andersen CY. Children born after autotransplantation of cryopreserved ovarian tissue: a review of 13 live births. Ann. Med. 43, 437-450 (2011).
114. Schmidt KT, Resendahl M, Ernst E. Autotransplantation of cryopreserved ovarian tissue in 12 women with chemotherapy-induced premature ovarian failure: the Danish experience. Fertil. Steril. 95, 695-701 (2011).
115. Premature Ovarian Insufficiency Registry. www.poiregistry.org
116. Panay N, Fenton A. Premature ovarian insufficiency: working towards an international registry. Climacteric 15, 295-296 (2012).
117. Cooper AR, Baker VL, Sterling EW et al. The time is now for a new approach to primary ovarian insufficiency. Fertil. Steril. 95, 1890-1897 (2011).
118. Falorni A, Minarelli V, Eads CM et al. A clinical research integration special program (crisp) for young women with primary ovarian insufficiency. Panminerva Med. PMID: 25288327 (2014) (Epub ahead of print).
119. Joachim CM, Eads CM, Persani L, Yurttas Beim P, Nelson LM. An open letter to the primary ovarian insufficiency community. Minerva Ginecol. 66, 519-520 (2014).
120. Rafique S, Sterling EW, Nelson LM. A new approach to primary ovarian insufficiency. Obstet. Gynecol. Clin. North Am. 39, 567-586 (2012).
121. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 428, 145-150 (2004).
122. White YA, Woods DC, Takai Y et al. Oocyte formation by mitotically active germ cells purified from ovaries of reproductive age women. Nat. Med. 18, 413-421 (2012).